Company intelligence / Profile preview
CSL Behring
- Ownership
- Public · CSL
- Employees
- ~27000
- Development stage
- Other
Overview
CSL Behring offers a broad range of quality plasma-derived and recombinant therapies for rare and serious diseases. Their products include treatments for coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders.
- Therapeutic areas
- PulmonologyCardiovascularImmunologyHematologyRare DiseasesNeurology
- Modalities
- Plasma-derived therapiesRecombinant protein technologyCell and gene therapy
- Industry
- Pharma
Drug pipeline
57 assets56 more assets in the full pipeline.
Beyond the preview
Go deeper on CSL Behring.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL Behring.